Updated September 14, 2026
A report published on March 4, 2024 described NOW Foods testing twelve creatine gummy products, with five reported as severely understrength. The report says NOW's usual external laboratory partners could not perform this gummy testing. This historical sample is not an estimate of today's market failure rate, and the report alone does not establish why each product was understrength.
For a gram-scale creatine gummy brief, distinguish the requested label amount, ingredient input and measured finished-product result before evaluating process risks.
Illustrative mass budget, not a product specification: three 4 g gummies weigh 12 g in total. Allocating 5 g of that mass to creatine monohydrate leaves 7 g for the rest of the formula, so the monohydrate share is 5 ÷ 12 × 100 = 41.7%. At three 5 g pieces, the same input occupies 33.3%. These assumed piece weights are not a claimed market range, and ingredient input is not a finished-product assay result.
Three project-specific controls deserve investigation; none by itself diagnoses a failed market sample:
Ask the manufacturer to demonstrate deposit-weight control and active distribution at the proposed formula and production scale. A composite assay describes the tested composite; it does not by itself establish uniformity across individual pieces. Request the sampling plan and the evidence used to assess variation.
Assess texture at the proposed ingredient load, not just in a lower-load flavor sample. A label amount below 5 g per serving is not evidence of manufacturing failure. The appropriate target belongs in the product brief and its substantiation; it cannot be inferred from a competitor dose or a sensory sample.
Creatine monohydrate can convert to creatinine in solution, with conversion accelerated by lower pH and higher temperature. In a gummy project, the relevant risks are heat and moisture exposure during manufacturing, followed by long-term storage in a mildly acidic matrix. Release testing alone cannot establish a 24-month shelf life.
Common possibilities that a brand's quality team should investigate include:
Supplier evaluation can reveal evidence gaps before an order. It does not eliminate the need for batch acceptance, complaint handling and ongoing quality controls.
A meaningful third-party report carries a sample code, a batch number, a report date and an issuing laboratory. Those four fields let you connect the number to a physical lot. A document that says "creatine gummies — pass" with no traceable identifiers connects to nothing.
For any purported result, ask for the sample name, sample code, batch identity, method, units, report date and issuing party. Then confirm that the tested sample represents the formula and lot relevant to the commercial claim.
Ask: what changes between the sample I approve and the first commercial batch? Request documented scale-transfer controls, validation evidence and change approval responsibilities. Experience or certification alone does not answer that question.
Request the stability protocol, available results and the technical justification for the proposed shelf life. Distinguish accelerated screening from real-time observations, identify unobserved timepoints, and agree how the claim will be reviewed as commercial-batch data accumulates.
Agree in writing who investigates unexpected results, controls affected stock, communicates with the sales channel and funds any necessary corrective action. Independent verification is one control alongside batch release, stability monitoring and enforceable quality arrangements; it cannot guarantee that problems will not occur.
Compare offers on the same amount basis and servings per bottle. For illustration only, a 60-piece bottle provides 20 servings at three gummies per serving, or 15 at four gummies per serving. A lower bottle price need not mean a lower cost per comparable serving.
Record piece weight, pieces per serving and the agreed creatine reporting basis together. A higher target loading still needs evidence for the proposed formula, process and package; it is not proof of better quality.
An understrength result needs a structured investigation: check reporting basis, sample identity, analytical suitability, production controls and stability evidence. Do not infer a universal gummy dose limit or a specific failure mechanism from one reported result.
If you are scoping a creatine gummy project, the private label creatine gummy manufacturing page connects material identity, serving design, stability, testing and release questions to a structured project brief.
This article discusses supplier-evaluation principles and publicly reported market testing. It does not allege that any named brand intentionally misstated potency.
No. The March 2024 report described five severely understrength products in a twelve-product sample. That is 41.7% of that sample, not a representative or current market-wide rate.
Creatine monohydrate can convert to creatinine in solution, with faster conversion at lower pH and higher temperature. Manufacturing heat exposure, moisture and an acidic gummy matrix therefore need to be considered in process and stability studies.
Ask for the complete report, sample and lot identity, reporting basis, matrix-suitable method, and a documented technical basis for the proposed shelf life.
Send the creatine form, label amount, serving design, intended market and the evidence your quality team expects. The Brooklyn office will route the material-load, analytical-method and scale-transfer questions before commercial terms are discussed.
Request a QuoteCompare quote inputs, MOQ, lead-time stages and cost drivers.
Read article →A practical comparison of pectin and gelatin gummy bases for supplement brands — texture, heat resistance, dietary posit…
Read article →